Basel (Switzerland) and Mannheim (Germany), May 4, 2021 – VAXIMM AG, a Swiss/German biotech company focused on developing an oral plug and play DNA vaccination technology to stimulate patients’ cytotoxic T-cells targeting a wide range of cancer-related antigens, announced today that the Company will participate in several scientific and industry events this month.
Dr. Heinz Lubenau, Chief Executive Officer of VAXIMM, and the management team will attend the following conferences:
18th CIMT Annual Meeting
May 10-12, 2021, Virtual Event
– To schedule a meeting with the Company, please contact info@vaximm.com.
21st Bio€quity Europe
May 17-19, 2021, Virtual Event
– Company presentation.
– To request a meeting, please sign up through the event’s partneringONE meeting system.
SACHS FORUM: 7th Annual Immuno-Oncology Innovation Forum
May 18-20, 2021, Virtual Event
– Company presentation.
– Panel discussion “Latest Advances in Cell & Gene Therapies.”, 6:50 pm CEST, 19 May.
– To schedule a meeting, please sign up in the event’s online meeting system.
17th Annual Anglonordic Life Science Conference
May 25-26, 2021, Virtual Event
– Company presentation during session, “Biotech Investment and Technology Investment,” 12 pm CEST, 26 May.
– To schedule a meeting, please sign up in the online meeting system.
For updates, please see the Events section of the Company’s website.
About VAXIMM
VAXIMM is a privately held, Swiss/German biotech company that is developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM’s plug and play DNA vaccination technology is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic T-cells to target a wide range of cancer-related antigens. The Company has a pipeline of complementary development candidates targeting different tumor structures. Lead product candidate, oral VXM01, activates killer cells targeting tumor-specific vasculature and certain immune-suppressive cells, thereby increasing immune cell infiltration in solid tumors. VXM01 is currently in clinical development for several tumor types, including brain cancer. As part of a scientific collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer Inc., VAXIMM has an ongoing clinical trial evaluating VXM01 in combination with the human anti-PD-L1 antibody, avelumab. VAXIMM’s neoantigen program is currently in preclinical development; the Company’s platform allows for fast manufacturing of personalized T-cell cancer vaccines and may overcome key issues faced by other neoantigen approaches. A clinical Phase I basket study in collaboration with NEC Corporation is in preparation. VAXIMM also has a collaboration agreement with China Medical System Holdings (CMS), granting CMS full rights in China and other Asian countries (excluding Japan) to VAXIMM’s existing programs.
VAXIMM’s investors include: BB Biotech Ventures, BCM Europe, BioMed Partners, CMS, M Ventures, NEC and Sunstone Capital. VAXIMM AG is headquartered in Basel, Switzerland. Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company’s development activities. For more information, please visit www.vaximm.com and follow us on LinkedIn.
Contact:
VAXIMM AG
Dr. Heinz Lubenau
Phone: +49 621 8359 687 0
Email: info@vaximm.com
Media Inquiries:
MC Services AG
EU: Katja Arnold
USA: Laurie Doyle
Phone EU: +49 89 210228 0
Phone USA: +1 339 832 0752
Email: vaximm@mc-services.eu
